MigraineActive ingredient
Atogepant
CGRP receptor antagonist (gepant)1 FDA label read
Atogepant is sold as Qulipta and is the preventive-only gepant: a once-daily tablet approved for the preventive treatment of migraine in adults, with dosing that differs between episodic and chronic migraine. It is not a medication for stopping an attack that has started.
Highlights of the labels
- Qulipta
- Preventive treatment of migrainecovers migraine
- Supply
- Prescription only
- Generic
- None approved
- Boxed warning
- None in these labels
Brands and what each one is approved for
One active ingredient can hold several separate FDA approvals. They are different documents with different approved uses, and mixing them up is the most common mistake made about these medications.
| Brand | What its label approves | Supply | Label version |
|---|---|---|---|
| QuliptaAbbVie Inc. | What its label approvesPreventive treatment of migraineCovers migraine | SupplyPrescription | Label version30 September 2025 |
How it works
Atogepant blocks the CGRP receptor and is taken on a schedule rather than in response to pain: once daily, with or without food, every day regardless of whether an attack occurs.
Mechanism of action, Qulipta label
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.
What the FDA approved it for
The approved uses, as worded in the label.
- QULIPTA is indicated for the preventive treatment of migraine in adults.
- QULIPTA is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults.
Forms and strengths
The presentations and strengths listed in the label.
- QULIPTA 10 mg is supplied as white to off-white, round biconvex tablets debossed with "A" and "10" on one side.
- Tablets: 10 mg, 30 mg, and 60 mg.
How the label says it is taken
What the label states about administration. It is not a dosing instruction for any individual.
- QULIPTA is taken orally with or without food.
- For episodic migraine, the recommended dosage is 10 mg, 30 mg, or 60 mg taken once daily.
- For chronic migraine, the recommended dosage is 60 mg taken once daily.
- Severe Renal Impairment or End-Stage Renal Disease: Episodic migraine: 10 mg once daily. Chronic migraine: Not recommended.
Most common adverse reactions
The adverse reactions the label reports as most common.
most common adverse reactions (incidence at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.
Warnings and precautions
The warnings and precautions section of the label.
- Hypersensitivity Reactions: If a hypersensitivity reaction occurs, discontinue QULIPTA and initiate appropriate therapy. Severe hypersensitivity reactions have included anaphylaxis and dyspnea. These reactions can occur days after administration.
- Hypertension: New-onset or worsening of pre-existing hypertension may occur.
- Raynaud's phenomenon: New-onset or worsening of pre-existing Raynaud's phenomenon may occur.
Contraindications
Situations in which the label states the medication must not be used.
- QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.
- Reactions have included anaphylaxis and dyspnea.
Drug interactions
Interactions the label singles out.
- Recommended dosage modifications: Strong CYP3A4 Inhibitors:
- Episodic or chronic migraine: 10 mg once daily Strong CYP3A4 Inducers:
- Episodic migraine: 60 mg once daily (monitor for reduced efficacy).
- Chronic migraine: Not recommended.
- Moderate CYP3A4 Inducers:
- Episodic migraine: 60 mg once daily.
Pregnancy and breastfeeding
The opening of the pregnancy section of the label. The full section is longer and is in the source document.
Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors outcomes in women who become pregnant while taking QULIPTA. Patients should be encouraged to enroll by calling 1-833-277-0206 or visiting http://empresspregnancyregistry.com. Risk Summary There are no adequate data on the developmental risk associated with the use of QULIPTA in pregnant women.
Generic or brand
There is no FDA-approved generic atogepant: the register lists the brand application only.
The FDA label database lists no approved generic application for this ingredient.
What affects the cost
Qulipta is brand-only. Acquisition cost is per tablet at brand level; what a person pays depends on insurance coverage. This site sells nothing and links to no sellers.
What pharmacies pay for it
These are acquisition costs: what pharmacies in the United States pay on average to buy the medication, published weekly by the Centers for Medicare and Medicaid Services. They are not retail prices and not what a person pays at the counter, which depends on insurance, pharmacy and discount programs. They are useful as an objective floor and for seeing how far a brand sits above its generic.
| Measured | Brand |
|---|---|
| per tablet, capsule or pen | Brand$38.41 (range $36.54 to $38.47, 102 listings) |
Median of 102 listings. Effective dates 2025-12-17 to 2026-08-19, file dated 2026-08-26.
Compared with other medications
What the labels do not do is compare one medication against another. These pages put two of them side by side.
Common questions
- Is Qulipta for episodic or chronic migraine?
- Both, at different doses. The label sets 10, 30 or 60 mg once daily for episodic migraine and 60 mg once daily for chronic migraine.
- Can Qulipta stop a migraine attack?
- Acute treatment is not among its indications: the label covers preventive treatment of migraine in adults. The gepants approved for acute treatment are ubrogepant and rimegepant, each with its own page here.
- Why does the label change the dose with other medications?
- Qulipta's dosing moves with drug interactions: with strong CYP3A4 inhibitors the label sets 10 mg once daily, and with strong CYP3A4 inducers it sets 60 mg for episodic migraine while advising monitoring for reduced efficacy. The interactions section on this page quotes the label.
Other medications under migraine
Whether each one carries an FDA approval for this use is marked on its page and in this list.
Sources
Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.
FDA prescribing information for Qulipta
AbbVie Inc.. Label version 19, effective 30 September 2025.
Each stripe is one section of the label, each division in a stripe one entry in that section.
Page last updated 29 August 2026
Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.